Abstracts tagged "cytokines"

Abstract Number: 1441 • 2012 ACR/ARHP Annual Meeting
Epstein Barr Virus CD40 Functional Mimic Latent Membrane Protein-1 Drives Cellular Molecular Mimicry in the Presence of Epstein Barr Virus Nuclear Antigen-1 in a Novel Murine Model of Lupus-Like Disease
Melissa E. Munroe¹, Jourdan R. Anderson², Timothy F. Gross³, Laura L. Stunz⁴, Gail A. Bishop⁴ and Judith A. James⁵, ¹Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Arthritis & Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴The University of Iowa, Iowa City, IA, ⁵Oklahoma Medical Research Foundation; University of Oklahoma Health Sciences Center, Oklahoma City, OK
Background/Purpose: Immune dysregulation underlies the complex pathogenesis of SLE. Infection with Epstein Barr Virus (EBV) and expression of latent protein Epstein Barr Virus Nuclear Antigen-1…
Abstract Number: 883 • 2012 ACR/ARHP Annual Meeting
Role of Phospholipase D1 (PLD1) in the Expression of Proinflammatory Genes in Rheumatoid Arthritis Synovial Fibroblasts (RASF)
Sean C. Friday¹ and David A. Fox², ¹Rheumatology, The University of Michigan, Ann Arbor, MI, ²Rheumatology/Int Medicine, Univ of Michigan Med Ctr, Ann Arbor, MI
Background/Purpose: Interleukin-17 (IL-17) and Tumor Necrosis Factor alpha (TNFa), when co-applied to RASF, induce synergistic expression of proinflammatory genes such as IL-6 and IL-8. Work…
Abstract Number: 2311 • 2012 ACR/ARHP Annual Meeting
Total Glucosides of Paeony Th1 and Th17 Cell Differentiation by Blocking STAT1 and STAT3 Activation in Vivo
Ningli Li¹ and JP Lin², ¹Shanghai Institute of Immunology, Institute of medical sciences, Shanghai Jiao Tong University School of Medicine, Shanghai, China, ²Shanghai Institute of Immunology, Institute of medical sciences,Shanghai Jiao Tong University School of Medicine, Shanghai, China
Background/Purpose: Th1 and Th17 cells play very importent role in the lesions of human rheumatoid arthritis (RA). Total glucoside of paeony (TGP), an active compound extracted from…
Abstract Number: 1448 • 2012 ACR/ARHP Annual Meeting
Inhibition of Calcium/Calmodulin-Dependent Protein Kinase IV Suppresses the Autoimmunity in Lupus-Prone Mice
Kunihiro Ichinose¹, Atsushi Kawakami² and George C. Tsokos³, ¹Department of Immunology and Rheumatology, Unit of Translational Medicine, Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ²Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ³Medicine/Rheumatology, BIDMC, Harvard Medical School, Boston, MA
Inhibition of Calcium/Calmodulin-Dependent Protein Kinase IV Suppresses the Autoimmunity in Lupus-Prone Mice. Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic inflammatory disease associated with abnormal…
Abstract Number: 872 • 2012 ACR/ARHP Annual Meeting
Monocyte Chemoattractant Protein-1 and Eotaxin Are Associated with Parameters of Cardiac Dysfunction in Juvenile Dermatomyositis
Thomas Schwartz¹, Ivar Sjaastad², Berit Flatø³, Maria Vistnes¹, Geir Christensen¹ and Helga Sanner³, ¹Institute for Experimental Medical Research, Institute for Clinical Medicine, University of Oslo, Oslo, Norway, ²Institute for Clinical Medicine, University of Oslo, Institute for Experimental Medical Research, Oslo University Hospital, Oslo, Norway, ³Department of Rheumatology, Oslo University Hospital, Institute for Clinical Medicine, University of Oslo, Oslo, Norway
Background/Purpose : Juvenile dermatomyositis (JDM) is a vasculopathic disease affecting not only skeletal muscle and skin, but other organs as well. Previously we have shown…
Abstract Number: 2291 • 2012 ACR/ARHP Annual Meeting
Enhanced Release of S100A9 and Hepatocyte Growth Factor by the Epidermis in Systemic Sclerosis
Joanna Nikitorowicz Buniak¹, Christopher P. Denton¹, David J. Abraham² and Richard J. Stratton¹, ¹Centre for Rheumatology and Connective Tissue Diseases, UCL Medical School, London, United Kingdom, ²UCL Medical School, London, United Kingdom
Background/Purpose: Systemic sclerosis (SSc) is a severe disease of unknown aetiology characterised by cellular injury and activation in early stage, followed by autoimmunity and fibrosis.…
Abstract Number: 1307 • 2012 ACR/ARHP Annual Meeting
Anti-IL-6 Receptor Nanobody (ALX-0061) Seamless “First-in-Human” Phase I/II POC Study in Patients with Active RA On Stable MTX Treatment
Steven De Bruyn¹, Béla Gachályi², Bernadette Rojkovich³, Slavomir Bruk⁴, Petr Sramek⁵, Mariusz Korkosz⁶, Krzysztof Krause⁷, Pieter Schoen⁸, Laura Sargentini-Maier⁹, Joke D'Artois¹⁰, Katrien Verschueren¹⁰, Katelijne De Swert¹⁰, Gerhard Arold¹¹ and Josefin-Beate Holz¹², ¹Clinical Development, Ablynx N.V., Zwijnaarde, Belgium, ²Fázis I-es Klinikai Farmakológiai Vizsgálóhely, Péterfy Sándor Utcai Kórház, Budapest, Hungary, ³II. sz. Reumatológiai Osztály, Budai Irgalmasrendi Kórház Kht., Budapest, Hungary, ⁴Interni oddeleni, Nemocnice Trinec, Trinec, Czech Republic, ⁵Pharmaceutical Research Associates CZ, Praha, Czech Republic, ⁶Malopolskie Centrum Medyczne, Krakow, Poland, ⁷Specjalistyczny im. J. Gromkowskiego, Wojewodzki Szpital, Wroclaw, Poland, ⁸Project Management, Ablynx N.V., Zwijnaarde, Belgium, ⁹Pharmacology, Ablynx N.V., Zwijnaarde, Belgium, ¹⁰Clinical Development, Ablynx nv, Zwijnaarde, Belgium, ¹¹Medical Affairs, PRA International GmbH, Berlin, Germany, ¹²Chief Medical Officer, Ablynx N.V., Zwijnaarde, Belgium
Background/Purpose: ALX-0061 is a 26kD bispecific IL-6R targeting Nanobody® with monovalent binding to IL-6R and serum albumin. It effectively neutralizes IL-6 pathway activity in-vitro and…
Abstract Number: 740 • 2012 ACR/ARHP Annual Meeting
Select Soluble Inflammatory Mediators Are Detected Prior to and Increase At Systemic Lupus Erythematosus Classification
Melissa E. Munroe¹, Jourdan R. Anderson², Julie M. Robertson³, Timothy B. Niewold⁴, George C. Tsokos⁵, Michael P. Keith⁶, John B. Harley⁷ and Judith A. James⁸, ¹Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Arthritis & Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Section of Rheumatology and Gwen Knapp Center for Lupus and Immunology Research, University of Chicago, Chicago, IL, ⁵Medicine/Rheumatology, BIDMC, Harvard Medical School, Boston, MA, ⁶Rheumatology, Walter Reed National Military Medical Center, Bethesda, MD, ⁷Division of Rheumatology and The Center for Autoimmune Genomics & Etiology, University of Cincinnati, Cincinnati Children's Hospital Medical Center; US Department of Veterans Affairs Medical Center, Cincinnati, OH, ⁸Arthritis & Clinical Immunology, Oklahoma Medical Research Foundation; Oklahoma University Health Sciences Center, Oklahoma City, OK
Background/Purpose: The processes that lead to clinical illness in systemic lupus erythematosus (SLE) years before diagnosis are not well characterized. Several cytokines have been associated…
Abstract Number: 2679 • 2012 ACR/ARHP Annual Meeting
Loss of Caspase 8 in Dendritic Cells Induces a Systemic Lupus Erythematosus-Like Disease That Is Independent of the Necroptosome
Carla M. Cuda¹, Alexander V. Misharin², Rana Saber², G. Kenneth Haines III³, Jack Hutcheson⁴, Chandra Mohan⁵ and Harris R. Perlman⁶, ¹Medicine / Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL, ²Medicine/Rheumatology, Northwestern University, Chicago, IL, ³Department of Pathology, Yale University, New Haven, CT, ⁴Internal Medicine - Rheumatic Diseases, University of Texas Southwestern Medical Center, Dallas, TX, ⁵Internal Medicine/Division of Rheumatology, University of Texas Southwestern Medical Center, Dallas, TX, ⁶Feinberg School of Medicine, Northwestern University, Chicago, IL
Background/Purpose: Systemic lupus erythematosus (SLE) is a multi-organ, destructive autoimmune disease characterized by pathogenic autoantibodies. Though it is accepted that dendritic cells (DCs) play an…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].